This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, D.-G.
Right arrow Articles by Kang, M.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, D.-G.
Right arrow Articles by Kang, M.-W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2003, p. 3768-3773, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3768-3773.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Efficacies of Vancomycin, Arbekacin, and Gentamicin Alone or in Combination against Methicillin-Resistant Staphylococcus aureus in an In Vitro Infective Endocarditis Model

Dong-Gun Lee,1 Hye-Sun Chun,2 Dong-Seok Yim,3 Su-Mi Choi,1 Jung-Hyun Choi,1 Jin-Hong Yoo,1 Wan-Shik Shin,1* and Moon-Won Kang1

Division of Infectious Diseases, Department of Internal Medicine,1 Clinical Research Institute,2 Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea3

Received 14 March 2003/ Returned for modification 9 June 2003/ Accepted 25 August 2003

We adopted an in vitro infective endocarditis model (IVIEM) to compare the efficacy of vancomycin (VAN), arbekacin (ABK), and gentamicin (GEN) alone or in combination. Using two strains of clinically isolated methicillin-resistant Staphylococcus aureus, one GEN susceptible (GS171) and one GEN resistant (GR153), fibrin clots were prepared and suspended in the IVIEM. Antibiotics were given as boluses every 6 h (q6h), q12h, or q24h or by continuous infusion with VAN, q12h or q24h with ABK, and q8h or q24h with GEN. For combination treatment, VAN q12h plus ABK q24h and VAN q12h plus GEN q24h were given. Fibrin clots were removed from each model at 0, 8, 24, 32, 48, and 72 h, and the bacterial densities were determined. The number of colonies within the fibrin clot was significantly decreased in all study groups compared with control groups (P < 0.001). When VAN and ABK were administered alone, the number of colonies was significantly lower in GS171 than in GR153 by 8 h after administration (P = 0.02) and was lowest in GS171 when ABK was administered q12h (P = 0.01). At 72 h, ABK or VAN alone produced equivalent bacterial reductions regardless of dosing frequency and GEN resistance. In GR153, VAN plus ABK showed an additive effect till 24 h, although VAN plus GEN showed indifference. Our data suggest that ABK could be used as an alternative to VAN in GEN-resistant staphylococcal endocarditis. An additive effect was seen when VAN and ABK were used together in GEN-resistant strains until 24 h; however, further studies are warranted for the clinical application of this combination.


* Corresponding author. Mailing address: Department of Internal Medicine, St. Mary's Hospital, 62 Yoido-Dong, Youngdeungpo-Gu, Seoul 150-713, Korea. Phone: 82-2-3779-1151. Fax: 82-2-780-3132. E-mail: symonlee{at}catholic.ac.kr.


Antimicrobial Agents and Chemotherapy, December 2003, p. 3768-3773, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3768-3773.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Kageyama, A., Torikoe, K., Iwamoto, M., Masuyama, J.-I., Shibuya, Y., Okazaki, H., Yazawa, K., Minota, S., Kroppenstedt, R. M., Mikami, Y. (2004). Nocardia arthritidis sp. nov., a New Pathogen Isolated from a Patient with Rheumatoid Arthritis in Japan. J. Clin. Microbiol. 42: 2366-2371 [Abstract] [Full Text]